Functional Fluidics supports pharmaceutical and academic partners in evaluation, development and bringing new therapies to market.

Specialized Testing Expertise

Functional Fluidics specializes in assessing blood function, with a specific focus on red blood cell health. Our proprietary testing platforms assess key properties underpinning RBC function and survival.

While well-positioned to address the needs of clients with large-scale validation studies, we also provide insights into the individual patient-level response critical for development of personalized medical applications. Our CLIA-certified lab is available for both high-throughput cell function testing, and to assaying unique patient samples, where you may be asking the questions related to drug safety of mechanisms of action.

 

 
02-4
 

 

Our Biomarkers for Red Blood Cell Health

Whether your drug is in preclinical development or it already been approved by the FDA, healthcare providers will need well-validated biomarkers to objectively assess the impact on red blood cell health, and ultimately patient health. Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.

  • Flow Adhesion:
    Our Flow Adhesion Assays capture the adhesive properties of an individual’s blood cells during conditions that simulate physiologic blood flow.
  • Mechanical Fragility :
    Our Membrane Fragility assay determines the stability of the intact RBC membrane, which indicates the health of the RBC and may predict RBC survival

Learn More

img03

 

 

Contract Research Services

Functional Fluidics provides testing solutions to support our pharmaceutical and academic research partners across the continuum of drug development, with a specialized focus on red blood cell modifying therapies.

  1. Biomarkers:Our biomarkers objectively assess the impact of a drug on red blood cell health and survival, thus reducing scientific and regulatory risks.
  2. Network:Our strong network of healthcare providers allows Functional Fluidics to facilitate clinical studies/trials for our pharma partners.
  3. Expertise: Our experienced scientific and technical team can assist in developing a successful research strategy.
10
 
 
09
 

Pre-Clinical Validation Studies

Functional Fluidics biomarkers can determine the effects of your therapy on red blood cell function and assess dose-dependent pharmacodynamic effects in an in vitro context. Blood samples from both human and animal models (including mice) can be used.

Learn More

1180807912411244.RoClR4ZMZHqCZURnNzpL_height640

Clinical Studies

Functional Fluidics biomarkers can determine the effects of your experimental therapy on red blood cell function and assess dose-dependent pharmacodynamic effects in the context of clinical trials by assessing blood samples from study subjects treated with your therapy.

Learn More

01-2
 
07
 

Post-Marketing Studies

Functional Fluidics biomarkers can determine the effects of your FDA-approved therapy on red blood cell function and assess a proposed mechanism of action or identify optimal dosages in the context of a post-marketing study.

Learn More

1180807912411244.RoClR4ZMZHqCZURnNzpL_height640
 

Why Choose Functional Fluidics?

  • New Project

    Proprietary Lab Tests

  • New Project(1)

    CLIA Certified Lab

  • New Project(5)

    Complex Tests Experience

  • New Project(2)

    Leadership Access

  • New Project(3)

    Specialized Staff

  • New Project(4)

    Strong Industry Relationships



Functional Fluidics Assays

Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.

  • 10
    Flow Adhesion of whole blood on VCAM-1 (FA-WB-VCAM)
    LEARN MORE
  • 11
    Flow Adhesion of whole blood on P-Selectin (FA-WB-Psel)
    LEARN MORE
  • 12
    Mechanical Fragility – Normoxia (MF)
    LEARN MORE
 

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS)

13
 
    

Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive episodes (VOEs) that produce severe pain, organ damage, and early death. Lack of reliable biomarkers to objectively define VOEs, hinders the development of clinically useful interventions to improve the care for these patients.

Functional Fluidics recently participated in a ground-breaking study involving sickle cell patients. This non-interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.

The study data suggest that Functional Fluidics FA-WB-VCAM assay may serve as a predictive biomarker for impending VEEs, and a monitoring biomarker to assess response to SCD-modifying therapies.

LEARN MORE
04-1    

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers

Functional Fluidics Biomarker Assay Featured in ELIPSIS article in American Society of Hematology (ASH) Blood Magazine

Key Points

  • Feasibility of monitored out-of-hospital pain and patient-reported VOC days as endpoints for clinical trials in SCD is demonstrated.
  • ePROs, actigraphy, and laboratory biomarkers enable improved identification and assessment of in-hospital and out-of-hospital VOCs.
LEARN MORE
blood
 

Publications

FLOW ADHESION

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers

This non interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.

MECHANICAL FRAGILITY

Red Blood Cell Mechanical Fragility as Potential Metric for Assessing Blood Damage Caused by Implantable Durable Ventricular Assist Devices: Comparison of Two Types of Centrifugal Flow Left Ventricular Assist Devices.

Implantable Ventricular Assist Devices (VADs) have become a treatment of choice for patients with end-stage heart failure or cardiogenic shock, significantly increasing both survival rates and the quality of life of patients.

MECHANICAL FRAGILITY

Individual Variability in Response to a Single Sickling Event for Normal, Sickle Cell, and Sickle Trait Erythrocytes

Hemoglobin S (Hb-S) polymerization is the primary event in sickle cell disease causing irreversible damage to red blood cell (RBC) membranes over repeated polymerization cycles.

FLOW ADHESION

Sevuparin blocks sickle blood cell adhesion and sickleleucocyte rolling on immobilized L-selectin in a dose dependent manner

Adhesion of sickle red blood cells (SSRBC) to the vascular endothelium may initiate and propagate vascular obstruction in sickle cell disease (SCD)

MECHANICAL FRAGILITY

Impact of Environment on Red Blood Cell ability to Withstand Mechanical Stress.

Susceptibility of red blood cells (RBC) to hemolysis under mechanical stress is represented by RBC mechanical fragility (MF), with different types or intensities of stress potentially emphasizing different perturbations of RBC membranes

MECHANICAL FRAGILITY

An Approach to Measuring RBC Haemolysis and Profiling RBC Mechanical Fragility

Red blood cells (RBC) can be damaged by medical products, from storage or from disease. Haemolysis (cell rupture and haemoglobin release) is often a key indicator, with mechanical fragility (MF) offering the potential to assess sub-haemolytic damage as well

FLOW ADHESION

Low Molecular Weight Heparin Inhibits Sickle Erythrocyte Adhesion to VCAM-1 through VLA-4 Blockade in a Standardized Microfluidic Flow Adhesion Assay

The vaso-occlusive events in sickle cell disease (SCD) begin in early childhood, warranting the need for more preventative and therapeutic interventions for those affected

MECHANICAL FRAGILITY

Impact of the Oscillating Bead Size and Shape on Induced Mechanical Stress on Red Blood Cells and Associated Hemolysis in Bead Milling

While in circulation, red blood cells (RBC) need to elastically undergo large deformations without lysing, an ability that may be compromised by cell membrane damage.

PLEASE COMPLETE THE FORM BELOW FOR MORE INFORMATION: